Pharmaceutical Technology

SEPTEMBER 11, 2023

With many biopharma companies outsourcing for manufacturing support, how can your organisation outpace the competition?

Competition 59

Competition Pharmaceutical manufacturing Manufacturing Biopharma 59

Pharmaceutical Technology

JULY 29, 2022

As the full consequences of the COVID-19 virus started to emerge, and many industries found themselves having to either suspend operations or move to remote working, the biopharma sector found itself on the front line facing unprecedented challenges. Manufacturing agility: Index score 6.5/10. R&D ecosystem - Index score 6.54/10.

Biopharma 59

Biopharma Manufacturing Government Engineering 59

pharmaphorum

JANUARY 24, 2023

Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. Since 2010, the UK has fallen from 4th to 98th place in overall trade balance in pharmaceuticals, due to fierce global competition, according to the MMIP.

Manufacturing 111

Manufacturing Medicine Government Pharmaceutical manufacturing 111

pharmaphorum

DECEMBER 28, 2022

M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009.

Pharma 119

Pharma Pharmaceutical manufacturing Pharmaceutical Manufacturing 119

PM360

SEPTEMBER 30, 2024

This article outlines how developers can utilize sustainability initiatives to boost revenue, reduce costs, and advance innovation, ensuring a strategic, long-term, and more sustainable position in today’s competitive landscape.

Manufacturing 52

Manufacturing Pharma Pharmaceutical Competition 52

European Pharmaceutical Review

DECEMBER 21, 2022

2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Defossilization of pharmaceutical manufacturing.

Manufacturing 97

Manufacturing Pharmaceutical Healthcare Healthcare 97

Clarivate

AUGUST 20, 2024

Top-line differences between list price and MFP obscure the impact of discounts and rebates that PBMs and MCOs can secure from manufacturers in exchange for coverage or preferred access. In highly competitive categories like diabetes, net price could be half of the list price.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52